News
Novo Nordisk A/S said it has implemented a global hiring freeze as the Danish maker of weight-loss drugs seeks to cut costs ...
Novo Nordisk (NVO) reportedly implemented a global hiring freeze as the Danish drugmaker seeks to cut costs and regain its ...
Makers of weight-loss drugs are expected to rake in more than $150 billion in revenue by the early 2030s, thanks to the ...
Novo Nordisk’s wildly popular GLP-1 drug Wegovy has been approved for use against a serious form of liver disease.
The launch marked Danish drugmaker Novo Nordisk's debut on the continent, ramping up competition with rival Eli Lilly.
The Food and Drug Administration approved Novo Nordisk's popular weight-loss drug Wegovy to treat a form of liver disease.
The side effect is rare, according to a new study, but is also the subject of multiple lawsuits, including two filed by Long ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback